Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Harvard Business School
Johnson and Johnson
McKesson
Baxter

Last Updated: January 24, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Ademetionine

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for Ademetionine?

Ademetionine is an investigational drug.

There have been 5 clinical trials for Ademetionine. The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2013.

The most common disease conditions in clinical trials are Liver Diseases, Cholestasis, and Drug-Induced Liver Injury, Chronic. The leading clinical trial sponsors are Beijing 302 Hospital, Zhejiang Hisun Pharmaceutical Co. Ltd., and Abbott.

There are two US patents protecting this investigational drug and seventeen international patents.

Recent Clinical Trials for Ademetionine
TitleSponsorPhase
36 Weeks Short-Term Optimization Treatment of Glucocorticosteroid in the Patients With Chronic Recurrent DILIBeijing 302 HospitalPhase 1/Phase 2
Efficacy and Safety of Glucocorticosteroid Treatment in the Patients With Chronic Recurrent DILIBeijing 302 HospitalPhase 1/Phase 2
Study With Heptral in Subjects With Liver Disease Due to Alcohol ConsumptionAscentPhase 3

See all Ademetionine clinical trials

Clinical Trial Summary for Ademetionine

Top disease conditions for Ademetionine
Top clinical trial sponsors for Ademetionine

See all Ademetionine clinical trials

US Patents for Ademetionine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Ademetionine   Start Trial Method and culture medium for improving pluripotent stem cell differentiation inducing efficiency NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (Kumamoto, JP)   Start Trial
Ademetionine   Start Trial Therapeutic nuclease compositions and methods University of Washington (Seattle, WA)   Start Trial
Ademetionine   Start Trial Methods of expressing products in mammalian cells INTREXON CEU, INC. (Blacksburg, VA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
McKesson
Mallinckrodt
Express Scripts
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.